MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Actinium Pharmaceuticals Inc

Затворен

1.72 5.52

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.69

Максимум

1.73

Ключови измерители

By Trading Economics

Приходи

-9.3M

-16M

Служители

31

EBITDA

-9.3M

-17M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+250.88% upside

Дивиденти

By Dow Jones

Следващи печалби

1.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

624K

49M

Предишно отваряне

-3.8

Предишно затваряне

1.72

Actinium Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

18.07.2025 г., 21:01 ч. UTC

Печалби

Charles Schwab Profit Jumps on Tariff Trading Surge -- 2nd Update

18.07.2025 г., 20:50 ч. UTC

Пазарно говорене
Печалби

Tech, Media & Telecom Roundup: Market Talk

18.07.2025 г., 20:50 ч. UTC

Пазарно говорене
Печалби

Auto & Transport Roundup: Market Talk

18.07.2025 г., 20:50 ч. UTC

Пазарно говорене
Печалби

Basic Materials Roundup: Market Talk

18.07.2025 г., 20:46 ч. UTC

Печалби

Strong Earnings Fuel Stock-Market Records This Week -- WSJ

18.07.2025 г., 20:39 ч. UTC

Придобивния, сливания и поглъщания

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18.07.2025 г., 20:36 ч. UTC

Печалби

3M Gives Investors a 'Beat and Raise.' The Stock Is Rising. -- Barrons.com

18.07.2025 г., 20:16 ч. UTC

Придобивния, сливания и поглъщания

Chevron-Hess Deal Close Is Good News for Wall Street's Takeover Arbitragers -- Barrons.com

18.07.2025 г., 20:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

18.07.2025 г., 20:02 ч. UTC

Пазарно говорене

Gold Higher to Close Out Week -- Market Talk

18.07.2025 г., 19:14 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Post Weekly Gains -- Market Talk

18.07.2025 г., 19:06 ч. UTC

Пазарно говорене

Oil Futures Snap Two-Week Winning Streak -- Market Talk

18.07.2025 г., 18:24 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Netflix, Sarepta, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, and More -- Barrons.com

18.07.2025 г., 18:19 ч. UTC

Печалби

American Express Shares Drop as Earnings Beat, Record Revenue Fail to Impress -- Barrons.com

18.07.2025 г., 18:11 ч. UTC

Придобивния, сливания и поглъщания

Oil CEOs Get Their Revenge on Biden's Antitrust Enforcers -- WSJ

18.07.2025 г., 18:11 ч. UTC

Печалби

Netflix Earnings Show That YouTube Is the Streamer to Fear -- Barrons.com

18.07.2025 г., 17:35 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Falls by 2 to 422 -- Market Talk

18.07.2025 г., 16:29 ч. UTC

Пазарно говорене

Crude Rally on EU's Russia Sanctions Peters Out -- Market Talk

18.07.2025 г., 16:28 ч. UTC

Придобивния, сливания и поглъщания

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18.07.2025 г., 16:22 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Netflix, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, Sarepta, and More -- Barrons.com

18.07.2025 г., 16:20 ч. UTC

Пазарно говорене
Печалби

Financial Services Roundup: Market Talk

18.07.2025 г., 16:20 ч. UTC

Пазарно говорене
Печалби

Tech, Media & Telecom Roundup: Market Talk

18.07.2025 г., 16:20 ч. UTC

Пазарно говорене
Печалби

Auto & Transport Roundup: Market Talk

18.07.2025 г., 16:20 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Energy & Utilities Roundup: Market Talk

18.07.2025 г., 16:20 ч. UTC

Пазарно говорене
Печалби

Basic Materials Roundup: Market Talk

18.07.2025 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

18.07.2025 г., 16:04 ч. UTC

Печалби

Charles Schwab Profit Jumps on Tariff Trading Surge -- Update

18.07.2025 г., 15:58 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

18.07.2025 г., 15:58 ч. UTC

Пазарно говорене

Aluminum Gains on U.S. Dollar Weakness, Scrap Imports -- Market Talk

18.07.2025 г., 15:47 ч. UTC

Пазарно говорене
Печалби

Netflix Shifting Focus to Engagement with New Content -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Actinium Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

250.88% нагоре

12-месечна прогноза

Среден 6 USD  250.88%

Висок 9 USD

Нисък 4 USD

Според 3 анализатори от Wall Street, предложили 12-месечна ценова цел за Actinium Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

3 ratings

3

Купи

0

Задържане

0

Продай

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.